Rankings · Capital
Insiders buying
Companies whose directors, officers and largest holders bought more shares on the open market than they sold over the last twelve months, from SEC Form 4 filings, ranked by the net amount bought. Share grants and option exercises are left out.
37 companies meet this test
Figures as of November 15, 2026
| # | Company | Grade | Net bought by insiders | Insiders buying | Market value |
|---|---|---|---|---|---|
| 1 | IMVTImmunovant, Inc. | not rated | $348.3M | 1 | $7.1B |
| 2 | SGPSpyGlass Pharma, Inc. | not rated | $221.5M | 15 | $1.1B |
| 3 | KYMRKYMERA THERAPEUTICS, INC. | F- | $107.9M | 1 | $10.9B |
| 4 | SNDASonida Senior Living, Inc. | D | $100M | 1 | $1.6B |
| 5 | STAASTAAR Surgical Co | B | $62.8M | 2 | $1.3B |
| 6 | KODKODIAK SCIENCES INC. | not rated | $60M | 1 | $7.3B |
| 7 | MANEVeradermics, Inc | not rated | $58.1M | 5 | $5.5B |
| 8 | GENBGenerate Biomedicines, Inc. | not rated | $50.3M | 6 | $1.6B |
| 9 | AHCOAdaptHealth Corp. | C- | $48.8M | 5 | $1B |
| 10 | BHCBausch Health Companies Inc. | A | $15.5M | 1 | $3.1B |
More rankings
A ranking orders companies by one stated measure. It is not a recommendation, and it says nothing about whether any share price is reasonable.